An FDA advisory committee recommended approval of Nektar Therapeutics Inc.'s inhaled insulin product, Exubera - offering hope to many Type I and Type II diabetics who, for more than 80 years, had to stick themselves with needles to control their glucose levels. (BioWorld Today)

As its first product nears the market for respiratory infections, Replidyne Inc. brought in $62.5 million in a Series D round. (BioWorld Today)

In what could be the largest vaccine transaction in history, GlaxoSmithKline plc offered to acquire ID Biomedical for $1.4 billion. (BioWorld Today)